HB-adMSCs for Crohn's Disease
This study is looking into a treatment for Crohn's disease using HB-adMSCs (Hope Biosciences Adipose Derived Mesenchymal Stem Cells). These are special cells taken from fat tissue. You could be eligible if you are between 18 and 65 years old and have been diagnosed with Crohn's disease for at least six months. The study aims to see if HB-adMSCs can improve the signs and symptoms of Crohn's disease, measured by changes in your Crohn's Disease Activity Index (CDAI) scores. The study is comparing HB-adMSCs to a placebo (a treatment with no active drug). The current status of this study is unclear, and it plans to enroll 46 participants.
- Study design
- This is a randomized, double-blind study comparing HB-adMSCs to a placebo, involving 46 participants (23 in each group).
- What's involved
- You would receive intravenous infusions (injections into a vein) of either HB-adMSCs or placebo at weeks 0, 2, 4, 8, 12, and 16.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your progress will be followed for 52 weeks after your first treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
HB-adMSCs for the Treatment of Crohn's Disease
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Thanh Cheng, MD · PRINCIPAL_INVESTIGATOR · Hope Biosciences Research Foundation
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Changes from Baseline in Crohns Disease Activity Index (CDAI) Scores.Week 0 (Visit 1) to Week 52 (Visit 9)
Changes from Baseline (Week 0) up to Week 52 in Crohn's Disease Activity Index (CDAI) scores. Specifically, clinical response defined as a reduction of at least 100 points in Crohn's Disease Activity Index (CDAI) from baseline. Score ranges from 0 (minimum) - 450 (maximum), the least being asymptomatic and the greatest being most severe.